SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Rail Vikas Nigam, Asian Paints and Torrent Pharmaceuticals to see some action today

30 Jun 2025 Evaluate

Rail Vikas Nigam (RVNL) has emerged as the lowest bidder (L1) from South Central Railway for Design, Supply, Erection, Testing and Commissioning for OHE upgradation of existing 1X25Kv system to 2X25Kv at feeding system with feeder and earthing works in DuvvadaRajahmundry & Samalkot- Kakinada Port section of Vijaywada Division under South Central Railway, total 195.5 RKM/391 TKM. Cost of work is Rs 213.22 crore. The said order is expected to be completed in 24 months.

Asian Paints has acquired the balance 40% of the equity share capital of White Teak for a consideration of Rs 188 crore from the promoters of White Teak. Accordingly, the company now holds 100% of equity share capital of White Teak, by virtue of which White Teak has become a wholly owned subsidiary of the company. The acquisition of the remaining stake in White Teak would be a next step forward in the company’s foray of being a complete home decor solution provider and in accordance with the Definitive Agreements entered into by the company with White Teak and the promoters of White Teak.

Torrent Pharmaceuticals has received approval for acquisition of 7,44,81,519 equity shares, representing 46.39% of the equity share capital of J.B. Chemicals & Pharmaceuticals on a fully diluted basis, from Tau Investment Holdings Pte, the promoter of the J.B. Chemicals & Pharmaceuticals for cash consideration, at a price of Rs 1,600 per equity share, aggregating to a total consideration of around Rs 11,917 crore. For this purpose, a share purchase agreement has been executed between the company, Promoter Seller and the J.B. Chemicals & Pharmaceuticals. The board of directors of the company in their meeting held on June 29, 2025, has approved the same.

Godrej Properties has acquired 43 acres of land in Panipat, Haryana to develop its fourth residential plotted township in North India. The project will have a revenue potential in excess of Rs 1,250 crore. This project will contain around 1.02 million sq. ft. of plotted residential development, offering attractive plot sizes along with exceptional lifestyle amenities. The site is strategically located with access from the National Highway and is close to a host of social infrastructure.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Doxil Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL), of Baxter Healthcare Corporation. Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi’s Sarcoma, and Multiple Myeloma. 

Piramal Enterprises has invested Rs 700 crore in Piramal Finance (PFL) (Formerly known as Piramal Capital & Housing Finance), a wholly owned subsidiary of the company by way of subscription to rights issue (Transaction). PFL will be utilizing the aforesaid investment towards business/ general corporate purposes. There is no change in the shareholding percentage of the company in PFL pursuant to the aforesaid investment. The Transaction being between the holding company and its wholly owned subsidiary, it is exempt from the purview of related party transactions. The interest of the promoter/ promoter group/ group companies of the Company is only to the extent of PFL being a wholly owned subsidiary.

Hindustan Copper has executed an MoU with Indian Oil Corporation to jointly participate in copper, critical minerals block auctions, develop and operationalize block for exploration and mining, mining and processing of minerals and share risks across the value chain. The purpose of the MoU is also to share investments and risks for the development, mining and processing from existing assets of the company.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: